These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28093280)

  • 1. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.
    Munzone E; Colleoni M
    Cancer Lett; 2017 Aug; 400():259-266. PubMed ID: 28093280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
    Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
    Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
    Jin HY; He W; Liu Q; Wang XF; Liu YF; Wei ZX
    Neoplasma; 2016; 63(4):607-16. PubMed ID: 27268925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
    Alagizy HA; Shehata MA; Hashem TA; Abdelaziz KK; Swiha MM
    Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):22-7. PubMed ID: 25528114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study.
    Shawky H; Galal S
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):195-202. PubMed ID: 25467387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer.
    Abdelmaksoud BA; Mohammed A; Toam MM
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):749-754. PubMed ID: 32212803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
    Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
    Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis.
    Bianco N; Palazzo A; Pagan E; Bagnardi V; Milano M; De Maio AP; Colleoni M
    Breast; 2021 Oct; 59():351-357. PubMed ID: 34407499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
    Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies.
    Petrelli F; Parati MC; Borgonovo K; Cabiddu M; Ghilardi M; Luciani A
    Eur J Cancer; 2021 Apr; 147():151-153. PubMed ID: 33667890
    [No Abstract]   [Full Text] [Related]  

  • 14. AKT1
    Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
    Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.
    Rabanal C; Ruiz R; Neciosup S; Gomez H
    World J Clin Oncol; 2017 Dec; 8(6):437-446. PubMed ID: 29291168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic chemotherapy in cancer treatment: new wine in an old bottle.
    Wu HL; Zhou HX; Chen LM; Wang SS
    Theranostics; 2024; 14(9):3548-3564. PubMed ID: 38948068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
    Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
    Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievements and challenges in the use of metronomics for the treatment of breast cancer.
    Scharovsky OG; Rico MJ; Mainetti LE; Perroud HA; Rozados VR
    Biochem Pharmacol; 2020 May; 175():113909. PubMed ID: 32173366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.